On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence

Karen Jaqueline Paredes-Ruiz, Karla Chavira-Ramos, Mario Orozco-Morales, Cimen Karasu, Alexey A. Tinkov, Michael Aschner, Abel Santamaría, Ana Laura Colín-González

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


The endocannabinoid system (ECS) is composed of endogenous cannabinoids; components involved in their synthesis, transport, and degradation; and an expansive variety of cannabinoid receptors. Hypofunction or deregulation of the ECS is related to pathological conditions. Consequently, endogenous enhancement of endocannabinoid levels and/or regulation of their metabolism represent promising therapeutic approaches. Several major strategies have been suggested for the modulation of the ECS: (1) blocking endocannabinoids degradation, (2) inhibition of endocannabinoid cellular uptake, and (3) pharmacological modulation of cannabinoid receptors as potential therapeutic targets. Here, we focused in this review on degradation/reuptake inhibitors over cannabinoid receptor modulators in order to provide an updated synopsis of contemporary evidence advancing mechanisms of endocannabinoids as pharmacological tools with therapeutic properties for the treatment of several disorders. For this purpose, we revisited the available literature and reported the latest advances regarding the biomedical properties of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors in pre-clinical and clinical studies. We also highlighted anandamide and 2-arachidonoylglycerol reuptake inhibitors with promising results in pre-clinical studies using in vitro and animal models as an outlook for future research in clinical trials.

Original languageEnglish (US)
Pages (from-to)2072-2097
Number of pages26
JournalNeurotoxicity Research
Issue number6
StatePublished - Dec 2021


  • 2-Aranchidonoylglycerol
  • Anandamide
  • Endocannabinoid metabolism
  • Endocannabinoid system
  • FAAH inhibitors
  • MAGL inhibitors

ASJC Scopus subject areas

  • General Neuroscience
  • Toxicology


Dive into the research topics of 'On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence'. Together they form a unique fingerprint.

Cite this